Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment

• Status: Not yet recruiting
• Trial end date: 2027-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective randomized controlled trial where quality of life and the effectiveness of treatment will be evaluated in 80 patients with confirmed unilateral primary aldosteronism ,randomly assigned to be either treated surgically with unilateral adrenalectomy or to receive medical treatment with eplerenone.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Göteborg University
• Collaborators: Karolinska Institutet; Umeå University
• Treatments: Eplerenone; Mineralocorticoid Receptor Antagonists; Mineralocorticoids

Criteria

Inclusion Criteria:

1. Patients with confirmed unilateral PA

2. Age 18-70 years

3. Candidate for surgical treatment

4. No contraindications for minimally invasive surgery or treatment with MRA

5. Understands oral and written information and provides oral and written informed consent.

Exclusion Criteria:

1. Unwilling or unable to undergo surgery

2. Unwilling to accept medical treatment for 12 months and not receiving standard treatment (surgery)

3. Impaired renal function with eGFR <45 ml/min/1,73m2

4. P-cortisol >138 nmol/L following 1-mg overnight dexamethasone suppression test.